Helena Jernberg-Wiklund
Overview
Explore the profile of Helena Jernberg-Wiklund including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
749
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Borgenvik A, Holmberg K, Bolin S, Zhao M, Savov V, Rosen G, et al.
Cancer Res
. 2022 Oct;
82(24):4586-4603.
PMID: 36219398
Significance: SOX9 facilitates therapy escape and recurrence in medulloblastoma via temporal inhibition of MYC/MYCN genes, revealing a strategy to specifically target SOX9-positive cells to prevent tumor relapse.
2.
Kalushkova A, Nylund P, Parraga A, Lennartsson A, Jernberg-Wiklund H
Epigenomes
. 2021 Dec;
5(4).
PMID: 34968247
Aberrant DNA methylation, dysregulation of chromatin-modifying enzymes, and microRNAs (miRNAs) play a crucial role in haematological malignancies. These epimutations, with an impact on chromatin accessibility and transcriptional output, are often...
3.
Nylund P, Parraga A, Haglof J, de Bruyne E, Menu E, Garrido-Zabala B, et al.
Cell Death Dis
. 2021 Feb;
12(2):167.
PMID: 33579905
Multiple myeloma (MM) is a heterogeneous haematological disease that remains clinically challenging. Increased activity of the epigenetic silencer EZH2 is a common feature in patients with poor prognosis. Previous findings...
4.
Alzrigat M, Jernberg-Wiklund H, Licht J
Epigenomes
. 2019 Feb;
2(3).
PMID: 30761216
The enhancer of zeste homolog 2 (EZH2) is the enzymatic subunit of the polycomb repressive complex 2 (PRC2) that exerts important functions during normal development as well as disease. PRC2...
5.
Alzrigat M, Parraga A, Majumder M, Ma A, Jin J, Osterborg A, et al.
Oncotarget
. 2017 Dec;
8(61):103731-103743.
PMID: 29262596
Multiple myeloma (MM) is a tumor of plasmablasts/plasma cells (PCs) characterized by the expansion of malignant PCs with complex genetic aberrations in the bone marrow (BM). Recent reports, by us...
6.
Alzrigat M, Parraga A, Jernberg-Wiklund H
Semin Cancer Biol
. 2017 Oct;
51:101-115.
PMID: 28962927
Multiple myeloma (MM) is a tumor of antibody producing plasmablasts/plasma cells that resides within the bone marrow (BM). In addition to the well-established role of genetic lesions and tumor-microenvironment interactions...
7.
Alzrigat M, Jernberg-Wiklund H
RNA Dis
. 2017 Jul;
4(2).
PMID: 28664185
We have previously presented the histone methyltransferase enhancer of zeste homolog 2 (EZH2) of the polycomb repressive complex 2 (PRC2) as a potential therapeutic target in Multiple Myeloma (MM). In...
8.
Lin Y, Liu H, Waraky A, Haglund F, Agarwal P, Jernberg-Wiklund H, et al.
J Cell Physiol
. 2017 Jan;
232(10):2722-2730.
PMID: 28112398
Increasing number of studies have shown nuclear localization of the insulin-like growth factor 1 receptor (nIGF-1R) in tumor cells and its links to adverse clinical outcome in various cancers. Any...
9.
Alzrigat M, Parraga A, Agarwal P, Zureigat H, Osterborg A, Nahi H, et al.
Oncotarget
. 2017 Jan;
8(6):10213-10224.
PMID: 28052011
Multiple Myeloma (MM) is a plasma cell tumor localized to the bone marrow (BM). Despite the fact that current treatment strategies have improved patients' median survival time, MM remains incurable....
10.
Zaghlool A, Halvardson J, Zhao J, Etemadikhah M, Kalushkova A, Konska K, et al.
Hum Mutat
. 2016 Jun;
37(9):964-75.
PMID: 27328812
Chromatin-remodeling factors are required for a wide range of cellular and biological processes including development and cognition, mainly by regulating gene expression. As these functions would predict, deregulation of chromatin-remodeling...